A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. - Wikidata - awgldk - TriplyDB

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.

http://www.wikidata.org/entity/Q34307924

about

Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature Novel immunotherapeutic strategies of gastric cancer treatment Targeting receptor tyrosine kinases in gastric cancer Gastric Cancer: New Drugs - New Strategies Targeted therapies for gastric cancer: current status.Treatment options in patients with metastatic gastric cancer: current status and future perspectives Anti-angiogenic therapies for advanced esophago-gastric cancer Targeting angiogenesis in esophagogastric adenocarcinoma.Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.Targeted therapies in gastric cancer and future perspectives.Molecular targeted therapy for advanced gastric cancer Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.New and emerging combination therapies for esophageal cancer.The progress of targeted therapy in advanced gastric cancer Bevacizumab combined with low-dose S-1 as maintenance therapy with a long progression-free survival in an elderly patient with heavily pre-treated advanced gastric cancer: A case report Evolving standards of care in advanced gastric cancer.Molecular targeted agents for gastric and gastroesophageal junction cancer.Current status of targeted therapies in advanced gastric cancer.Targeted therapy for gastric cancer.Novel targeted agents for gastric cancer.Targeted therapy for gastric cancer--current status.Angiogenesis-related agents in esophageal cancer.Metastatic gastric cancer treatment: a little slow but worthy progress.Targeting the human epidermal growth factor receptor 2 in esophageal cancer.Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.Recent advances and future trends in the targeted therapy of metastatic gastric cancer.Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment.Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.Vascular endothelial growth factor a inhibition in gastric cancer.How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.Clinical management of advanced gastric cancer: the role of new molecular drugs.Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.Current advances in targeted therapies for metastatic gastric cancer: improving patient care.Targeted therapies in gastric cancer treatment: where we are and where we are going.Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.Predictive biomarkers along gastric cancer pathogenetic pathways.Latest developments and emerging treatment options in the management of stomach cancer.

P2860

Q26741242-EE5DB7B2-018B-4C10-8B05-F800377E9375 Q27011232-B9DF99D1-BAF3-48E8-8D7E-93924D909CE9 Q27013050-7346B0F8-B54A-4576-BA08-D1690F8EF978 Q27028079-64882F3C-C04A-4F86-9B9D-E6D322669E6D Q34205672-FB5AB37E-E8EC-4CB7-B2A4-E2BA7CA63618 Q34661367-7E8754DE-5F24-4C1F-ADC7-9D28C0411909 Q34686222-1EC3DF91-59E4-4840-9821-597FA06BF415 Q35584958-B2C5126B-6304-4EE6-834E-B58C54ABCA04 Q35863874-0D0229DF-E5FA-4842-9A19-E72853CB8DEE Q36207040-0EDB9DB2-E42C-437F-AC98-3E046FB1687B Q36212825-34D2FBA3-3D19-4FAF-931D-61F60F69F00F Q36471685-169A25DA-96EC-40AD-BE43-820909A07E44 Q36705689-A2C94CBE-56F1-4DDA-820C-0CFFC46FB0A5 Q36822182-8F834157-9295-4B8A-ADC9-E0D89C3B1DBB Q36996728-DE7C8B2C-3BC1-4CBC-8FFE-54AD5FE1F167 Q37427269-BF2DD297-A127-4D5C-A77D-00690E44910C Q37641014-25629F1E-6F11-42D5-BB22-5EFE0439DFD2 Q37960206-580108A0-D57A-4200-A144-2E4E9926A202 Q37962816-CD8278DF-2A9F-4834-8E09-47B1BDCD8183 Q37996448-330A415E-C672-4387-99EC-F05AAA71E684 Q38007119-5B30D1FA-EFDE-4700-AD4D-02F1925EF794 Q38019657-62C46DEA-2D78-4214-9097-209FDDD95AFA Q38019898-36AFFE75-8E44-4F0B-A084-1F6EF992E325 Q38031884-B59762A9-E874-4968-B5C1-9CE731F09E1E Q38075499-DCD701BB-026F-4633-82F5-FFC35FC525BC Q38097675-30CCF142-BA9F-4640-A567-67B0B1ABD930 Q38161727-1259EA6C-D65A-433D-80E0-5E8E2847532D Q38199128-DDAF8586-8165-4491-A170-8931024E39F7 Q38216461-51BB5B49-7363-48D5-83AA-3D35EC21B2C0 Q38222270-3F563327-EBC4-49C4-AE18-9A670E7990D3 Q38226093-EEF965E3-4C34-4881-9150-0D81E1464C33 Q38241766-EDEF492E-A3CF-4458-8A79-A185306ACD6D Q38263841-86C8BC65-F43B-47C1-8ADF-0467921C7BA9 Q38578404-12D2BDB7-816A-4B01-8448-4332A811C444 Q38632917-8A6C7F14-FEB0-495A-A9C6-C1A4422AFC03 Q38720829-D620DFAC-896F-4AC7-88EB-88F686A76E93 Q38731943-A5BB69EF-1AAE-45E1-AB64-64C55255FB7C Q39067386-C47F94E1-F4D6-4F20-95AF-B0C08B56546A Q39170872-3000F4A8-2925-4772-8FD2-AC980410EDE4 Q41898734-D6E1DD16-561E-48D5-9BCA-AFD272742C78

P2860

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.

http://www.wikidata.org/entity/Q34307924

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase II study of bevacizuma ...... roesophageal junction cancers.

@ast

A phase II study of bevacizuma ...... roesophageal junction cancers.

@en

A phase II study of bevacizuma ...... roesophageal junction cancers.

@nl

type

label

A phase II study of bevacizuma ...... roesophageal junction cancers.

@ast

A phase II study of bevacizuma ...... roesophageal junction cancers.

@en

A phase II study of bevacizuma ...... roesophageal junction cancers.

@nl

prefLabel

A phase II study of bevacizuma ...... roesophageal junction cancers.

@ast

A phase II study of bevacizuma ...... roesophageal junction cancers.

@en

A phase II study of bevacizuma ...... roesophageal junction cancers.

@nl

P1433

Q34307924-F93E890F-D8F0-45D5-8421-EC97E72A5CF5

P1476

Q34307924-963F057D-172D-484C-8EAC-52496357671B

P2093

Q34307924-0363C5E7-E479-41B4-8682-61FB9BF53898

Q34307924-1EA6B444-900B-4D3B-83B4-E215B1602CEF

Q34307924-317C5745-122A-4109-A058-9A8680C803BC

Q34307924-336CA17E-850B-4AAB-978E-09998451D161

Q34307924-498CE6E2-6B0E-457D-A7AD-BE3FFBF44F59

Q34307924-4F9E359D-0546-43B9-8DCC-D38DF0FEBE39

Q34307924-868CC6E4-EF3A-4FF6-A784-FEFC854E6887

Q34307924-96676594-0BE2-4775-A00B-99825E2BCABF

Q34307924-AB6EF099-AFEE-4488-B1CA-39C7A89272ED

Q34307924-ADC45D07-D47A-4AF0-8614-89771915D99F

P2860

Q34307924-0E32C2BC-7166-413D-AD70-89F0446EF0C6

Q34307924-0EB5D17E-1DB7-41BD-819F-B7E55EDDAE6B

Q34307924-11714603-76EA-4DBB-9DA6-E979FFC109F9

Q34307924-1BE2FB30-3A7A-458C-9262-6CEA0C1BEB68

Q34307924-3D344B5F-9358-4AB9-B7C1-BA6D4055AA8D

Q34307924-4D44B185-2CA5-4E32-AEE3-90981BE4FFAB

Q34307924-620AA552-7A0A-4416-9224-DE6185305249

Q34307924-66FBCAD2-D996-40B3-AF5B-8947B1BF7DC4

Q34307924-670869AD-E069-4A67-AFFF-658F40FDCA6E

Q34307924-780BC419-E299-4255-A68B-562D1B42D6F1

P304

Q34307924-E7D8233D-83A8-47EB-B873-B522491DDFA6

P31

Q34307924-1C845380-E717-4120-9E49-8D2A401AFA88

P356

Q34307924-C208282A-83FC-45AA-9BE0-6F0ECBCC7D92

P433

Q34307924-7F88A1B8-8984-4928-980B-41384E911419

P478

Q34307924-EF726992-9C84-4461-8D99-4986ADACEC88

P577

Q34307924-0A37CE65-3E67-440C-9574-64FF9621057A

P5875

Q34307924-C981110F-2E25-45F6-AC01-D082EF3D7C77

P698

Q34307924-3C48CAF2-F514-40A0-9FBF-40C379645760

P921

Q34307924-61C3A1B3-123D-4972-8F3F-3FE20C34BDC6

P932

Q34307924-A38D1B92-FB6C-4639-A669-692A6B714F02

P356

P1433

Annals of Oncology

P1476

A phase II study of bevacizuma ...... roesophageal junction cancers.

@en

P2093

A F Shields

http://www.w3.org/2001/XMLSchema#string

B F El-Rayes

http://www.w3.org/2001/XMLSchema#string

B Patel

http://www.w3.org/2001/XMLSchema#string

D Smith

http://www.w3.org/2001/XMLSchema#string

K Almhanna

http://www.w3.org/2001/XMLSchema#string

L K Heilbrun

http://www.w3.org/2001/XMLSchema#string

M Zalupski

http://www.w3.org/2001/XMLSchema#string

N Hammad

http://www.w3.org/2001/XMLSchema#string

P A Philip

http://www.w3.org/2001/XMLSchema#string

S Dawson

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Angiogenesis: an organizing principle for drug discovery?

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

P304

1999-2004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ065

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42440535

http://www.w3.org/2001/XMLSchema#string

P698

20332133

http://www.w3.org/2001/XMLSchema#string

P921

P932

2980934

http://www.w3.org/2001/XMLSchema#string